MedTrace Logo

Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases

NCT07644754 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-06-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if radiotherapy to the prostate and PET-positive (positron emission tomography) metastasis will lead to radiological response on PSMA-PET (prostate specific membrane antigen-PET). Patients who receive combined androgen deprivation therapy for de novo metastasized prostate cancer and show an incomplete PSA-response (\>0,2 ng/ml after six months) and exhibit at least four bone metastases on PET-imaging at this time point (without metastases to organs) can take part in this study.

The main questions it aims to answer are:

• Does radiotherapy to the prostate and PET-positive metastases lead to a radiological response one year after radiotherapy? Researchers will analyze PET-imaging prior to radiotherapy to the prostate and metastases and one yeare thereafter.

Participants will:

* Continue taking combined androgen-deprivation therapy
* Receive a total of three PSMA-PET/CT scans
* Receive radiotherapy to the prostate and PET-positive metastases
* Visit the clinic every three months for 36 months
* Complete quality of life questionnaires at every visit

Conditions

  • Prostate Cancer
  • Prostate Cancer Metastatic Disease
  • Prostate Cancer Metastatic to Bone

Interventions

RADIATION

Radiotherapy to the prostate and to PSMA-PET positive metastases

Patients will receive radiotherapy to the prostate and to PSMA-PET postivie Metastases

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • University Hospital Dresden

    collaborator OTHER

  • Uniklinikum Giessen und Marburg

    collaborator UNKNOWN

  • University Hospital Augsburg

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Elgin Hoffmann, MD · Department of Radiation Oncology, University Hospital Tübingen

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-07-31
Completion
2031-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07644754 on ClinicalTrials.gov